Home » News » R&D Trends » Trovagene closes acquisition of CLIA laboratory assets

Trovagene closes acquisition of CLIA laboratory assets

Wednesday, February 8, 2012

Trovagene, a developer of trans-renal molecular diagnostics based in San Diego, Calif., has closed its acquisition of MultiGEN Diagnostics’ clinical laboratory assets. Trovagene previously announced the execution of the asset acquisition agreement on Jan. 6, 2012.

MultiGEN is a molecular diagnostics company focused on DNA sequence based identification services having IP protected technologies.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!